Membrane Target Detection for Leukemia Treatment

Summary

Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, most within a few years of diagnosis. Despite advances in our understanding of the disease, few improvements in the therapy of AML have been made. Collecting specimens from the blood and bone marrow will increase understanding of the effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on human AML-SCP to develop individualized therapies. We also found DPP4 is highly expressed in other hematological malignancies in our mouse model, thus we would like to use human samples to investigate the role of DPP4 in hematological malignancy development and the mechanism underlying, especially to deeply understand the role of DDP4 in leukemia.

Eligibility

Inclusion Criteria:

* All hematological malignancy patients.
* Must be 18 years old.

Exclusion Criteria:

* Participants with impaired decision-making capacities;
* Pregnant women or fetuses;
* Children (under 18 in Missouri, also dependent on State law);
* Non-viable neonates or neonates of uncertain viability (neonates=newborns);
* Non-English-speaking subjects;
* Prisoners.

Conditions2

Locations1 site

Browse More Trials